Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality, and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs…
Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality, and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs…
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Pulmonary arterial hypertension (PAH) is a rare, life-threatening disorder characterized by high blood pressure in the arteries of the lungs. It is a progressive condition marked by considerable…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the diagnosed prevalence of PH…
Pulmonary hypertension (PH) constitutes a group of rare diseases, including pulmonary arterial hypertension (PAH), yet the commercial potential for novel drugs approved for PH indications is…
Hypertension
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We…
Clarivate Epidemiology’s coverage of pulmonary hypertension (PH) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of PH for each…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key pulmonary hypertension patient populations covering 171 countries…